Probiotics in inflamatory bowel disease.
作者信息
Shanahan F
机构信息
Department of Medicine, National University of Ireland, Cork, Ireland.
出版信息
Gut. 2001 May;48(5):609. doi: 10.1136/gut.48.5.609.
Abstract
摘要
相似文献
1
Probiotics in inflamatory bowel disease.
Gut. 2001 May;48(5):609. doi: 10.1136/gut.48.5.609.
2
[Probiotic therapy using live combined bifidobacterium, lactobacillus and enterococcus for experimental colitis in rats model].
Zhonghua Nei Ke Za Zhi. 2010 May;49(5):418-21.
3
What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?
J Clin Nurs. 2010 Apr;19(7-8):904-16. doi: 10.1111/j.1365-2702.2009.03123.x.
4
[Probiotics and prebiotics for the treatment of inflammatory bowel disease].
Nihon Rinsho. 2005 May;63(5):850-8.
5
A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial.
J Zhejiang Univ Sci B. 2006 Dec;7(12):987-91. doi: 10.1631/jzus.2006.B0987.
6
Probiotics and functional abdominal bloating.
J Clin Gastroenterol. 2004 Jul;38(6 Suppl):S102-3. doi: 10.1097/01.mcg.0000128939.40458.25.
7
[Efficacy and safety of probiotics].
Rev Med Suisse. 2007 Oct 17;3(129):2350-4.
8
Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis.
Dis Colon Rectum. 2008 Dec;51(12):1828-36. doi: 10.1007/s10350-008-9394-1. Epub 2008 Jul 17.
9
Probiotics: using bacteria to improve health.
Harv Health Lett. 2002 Mar;27(5):1-3.
10
Effect of probiotic bacterial strains of Lactobacillus, Bifidobacterium, and Enterococcus on enteroaggregative Escherichia coli.
J Infect Chemother. 2010 Feb;16(1):10-8. doi: 10.1007/s10156-009-0007-2.
引用本文的文献
1
Engineered bacteria and bacterial derivatives as advanced therapeutics for inflammatory bowel disease.
Essays Biochem. 2025 Feb 27;69(2):EBC20253003. doi: 10.1042/EBC20253003.
2
Research on the Mechanism of HRP Relieving IPEC-J2 Cells Immunological Stress Based on Transcriptome Sequencing Analysis.
Front Nutr. 2022 Jul 15;9:944390. doi: 10.3389/fnut.2022.944390. eCollection 2022.
3
Improved functionality of Ligilactobacillus salivarius Li01 in alleviating colonic inflammation by layer-by-layer microencapsulation.
NPJ Biofilms Microbiomes. 2021 Jul 9;7(1):58. doi: 10.1038/s41522-021-00228-1.
4
Enhancement of intestinal epithelial barrier function by Weissella confusa F213 and Lactobacillus rhamnosus FBB81 probiotic candidates in an in vitro model of hydrogen peroxide-induced inflammatory bowel disease.
BMC Res Notes. 2020 Oct 20;13(1):489. doi: 10.1186/s13104-020-05338-1.
5
Compatibility, Cytotoxicity, and Gastrointestinal Tenacity of Bacteriocin-Producing Bacteria Selected for a Consortium Probiotic Formulation to Be Used in Livestock Feed.
Probiotics Antimicrob Proteins. 2021 Feb;13(1):208-217. doi: 10.1007/s12602-020-09687-y.
6
Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases.
Front Pharmacol. 2020 May 27;11:730. doi: 10.3389/fphar.2020.00730. eCollection 2020.
7
Diet therapy for inflammatory bowel diseases: The established and the new.
World J Gastroenterol. 2016 Feb 21;22(7):2179-94. doi: 10.3748/wjg.v22.i7.2179.
8
Pro-inflammatory potential of Escherichia coli strains K12 and Nissle 1917 in a murine model of acute ileitis.
Eur J Microbiol Immunol (Bp). 2013 Jun;3(2):126-34. doi: 10.1556/EuJMI.3.2013.2.6. Epub 2013 Jun 5.
9
The role of bacteria in the pathogenesis of inflammatory bowel disease.
Gut Liver. 2010 Sep;4(3):295-306. doi: 10.5009/gnl.2010.4.3.295. Epub 2010 Sep 24.
10
Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk.
Interdiscip Perspect Infect Dis. 2008;2008:626827. doi: 10.1155/2008/626827. Epub 2008 Oct 29.
本文引用的文献
1
Probiotics and inflammatory bowel disease: is there a scientific rationale?
Inflamm Bowel Dis. 2000 May;6(2):107-15. doi: 10.1097/00054725-200005000-00007.
2
Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents.
Am J Physiol Gastrointest Liver Physiol. 2000 Feb;278(2):G191-6. doi: 10.1152/ajpgi.2000.278.2.G191.
3
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Lancet. 1999 Aug 21;354(9179):635-9. doi: 10.1016/s0140-6736(98)06343-0.
4
Immunity and probiotics.
Immunol Today. 1999 Sep;20(9):387-90. doi: 10.1016/s0167-5699(99)01448-6.
5
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?
Gastroenterology. 1999 May;116(5):1246-9. doi: 10.1016/s0016-5085(99)70029-6.
6
Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.
Gastroenterology. 1999 May;116(5):1107-14. doi: 10.1016/s0016-5085(99)70013-2.
7
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther. 1997 Oct;11(5):853-8. doi: 10.1046/j.1365-2036.1997.00225.x.
Zotero 插件